S&P Futures
5,909.50 +3.50 (+0.06%) Dow Futures
43,549.00 +31.00 (+0.07%) Nasdaq Futures
20,491.00 +7.50 (+0.04%) Russell 2000 Futures
2,294.60 +3.40 (+0.15%) Crude Oil
69.56 +0.34 (+0.49%) Gold
2,747.00 +17.00 (+0.62%)
Ascentage Pharma Group International (ASPHF)
- PR Newswire
Registrational Phase III Studies of APG-2449 Cleared by China CDE for the Treatment of Patients with NSCLC
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that APG-2449, a FAK/ALK/ROS1 tyrosine kinase inhibitor (TKI), has been cleared by the Center for Drug Evaluation (CDE) of China's National Medical Product Administration (NMPA) to enter two registrational Phase III studies that will separately evaluate APG-2449 in patients with non-small
- PR Newswire
Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released the clinical data of olverembatinib (HQP1351), the company's novel drug candidate, in patients with succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST), in a Mini Oral at the 2024 European Society of Medical Oncology (ESMO) Congress.
